B. Read the following passage, and answer the questions (Q1-Q5).  오늘 수빈이는 친구 민지와 같이 옷을 사러 백화점에 갔습니다. 백화점 안은 쇼핑하러 온 사람들 때문에 아주 복잡했습니다. 수빈이는 요즘 유행하는 짧은 치마와 블라우스, 그리고 굽이 높은 샌들을 사고 민지는 운동할 때 (B) _____ 편한 바지와 티셔츠를 샀습니다. (C) 한국은 유행이 자주 바뀌어서 옷 사기가 어렵습니다. 민지는 캐나다에 계시는 아버지께 (D) _________ 얇은 편 자켓도 하나 샀습니다. 세일을 해서 반값으로 싸게 살 수 있었습니다. 그런데 현금이 모자라서 카드로 냈습니다. 수빈이하고 민지는 마음에 꼭 드는 옷을 싸게 사서 기분이 아주 좋았습니다.   5. 맞는 것을 고르세요(Which of the following is true?). (4pts) __________

C. Listen to the conversation, and answer the following questions (Q1-Q5). 5) 틀린 것을 고르세요. (Which is the INCORRECT answer?) __________ (4pts)

B. Listen to the conversation, and answer the following questions (Q1-Q5).  5) 맞는 것을 고르세요(Which of the following is true? __________ (4pts)

Please log into the following website and complete the assessment titled “ATI RN Pharmacology Online Practice 2023 B” www.atitesting.com I have completed the ATI RN Pharmacology Practice 2023 B by accessing this “quiz” through HonorLock.  RN Pharmacology Online Practice 2023 B – is open & available for completion.  ***Handwritten remediation & Individual Performance Profile submission due by Monday November 24th at 11:59pm. (See ATI Module for submission details.)

What happens to the iron ions that are released when red blood cells (RBCs) are broken down?

Describe the relationship between preload, afterload, and contractility. Include discussion of the Frank-Starling law as it relates to these relationships.

Lactose Intolerance 1. Background Definition: Inability to digest lactose, the main carbohydrate in milk and dairy products, due to lactase enzyme deficiency in the brush border of the small intestine. Pathophysiology: Undigested lactose remains in the intestinal lumen → osmotic diarrhea and bacterial fermentation → gas, bloating, and cramping. Types: Primary (genetic): Gradual loss of lactase after childhood (most common worldwide). Secondary (acquired): Due to mucosal injury (celiac disease, gastroenteritis, Crohn disease). Congenital: Rare, autosomal recessive, presents in infancy. Epidemiology: Very common globally; affects up to 90% of Asian, African, and Native American populations; less common in Northern Europeans. 2. History Symptoms: Bloating, flatulence, crampy abdominal pain, and watery diarrhea after ingestion of milk or dairy products. Symptoms occur 30 minutes to 2 hours after lactose ingestion. Risk factors: Increasing age, certain ethnic backgrounds, recent intestinal infection, or small bowel disease. Relief: Avoidance of dairy eliminates symptoms. 3. Exam Findings Usually benign; may show mild abdominal distension or hyperactive bowel sounds. Signs of dehydration if diarrhea severe. Otherwise normal physical exam. 4. Making the Diagnosis Gold standard: Hydrogen breath test — elevated breath hydrogen after lactose load indicates malabsorption. Common alternative: Lactose elimination and re-challenge — symptom resolution after lactose avoidance confirms diagnosis. Supportive tests: Stool acidity test (infants): Low stool pH due to fermentation. Small bowel biopsy: Rarely needed; shows decreased lactase activity (used to rule out secondary causes). 5. Management A. Dietary Lactose restriction or use of lactose-free dairy products. Many patients tolerate small amounts of milk with meals. B. Supplements Lactase enzyme replacement before dairy intake (e.g., Lactaid). Calcium and vitamin D supplementation to prevent deficiency in those avoiding dairy. C. Treat underlying cause (if secondary) Address intestinal mucosal disease (e.g., celiac disease, Crohn disease, gastroenteritis recovery).   A 23-year-old woman reports several months of bloating, flatulence, and crampy abdominal pain that occur about 1 hour after drinking milk or eating ice cream. She denies fever, weight loss, or blood in her stool. Physical examination is normal. Which of the following is the most appropriate diagnostic test to confirm lactose intolerance?

Peptic Ulcer Disease (PUD) 1. Background Definition: Mucosal erosions ≥5 mm in the stomach or duodenum that penetrate the muscularis mucosa, usually due to acid–pepsin injury and impaired mucosal defense. Pathophysiology: Helicobacter pylori infection → increased gastric acid + inflammation → mucosal damage. NSAID use → prostaglandin inhibition → decreased mucus and bicarbonate production. Less common causes: Zollinger-Ellison syndrome, physiologic stress, smoking. Epidemiology: Duodenal ulcers more common than gastric. Peak incidence 30–60 years; risk increases with NSAID use and H. pylori prevalence. Complications: Bleeding, perforation, gastric outlet obstruction, malignancy (gastric only). 2. History Typical symptoms: Epigastric pain (burning, gnawing) related to meals. Duodenal ulcer: Pain relieved by food, returns 2–3 h after eating. Gastric ulcer: Pain worsens with food. Associated findings: Bloating, nausea, early satiety, melena, hematemesis in bleeding ulcers. Risk factors: H. pylori infection, chronic NSAID or aspirin use, smoking, corticosteroids, stress, older age, prior ulcer. 3. Exam Findings Mild epigastric tenderness. Occult blood on rectal exam if bleeding. Severe pain with guarding or rebound suggests perforation. 4. Making the Diagnosis Gold standard: Upper endoscopy (EGD) with biopsy — confirms ulcer, rules out malignancy, and allows H. pylori testing. Required in patients with alarm features (age > 60, weight loss, anemia, vomiting, GI bleeding, early satiety). Commonly used tests: Noninvasive H. pylori testing (urea breath test, stool antigen) for low-risk patients. Barium study if endoscopy unavailable, but less sensitive. Notes: Gastric ulcers should always be biopsied to exclude carcinoma. If initial endoscopy negative and suspicion high, consider Zollinger-Ellison syndrome (fasting gastrin). 5. Management A. Lifestyle / Non-pharmacologic Stop NSAIDs/aspirin when possible. Avoid smoking, alcohol, caffeine. Eat smaller meals; manage stress. B. Medication Eradicate H. pylori (if positive): Triple therapy (14 days): PPI + clarithromycin + amoxicillin (or metronidazole if penicillin-allergic). Quadruple therapy: PPI + bismuth + tetracycline + metronidazole (preferred if clarithromycin resistance or prior macrolide exposure). Acid suppression: PPI (omeprazole, pantoprazole) for 4–8 weeks after therapy. H2 blocker as alternative if mild disease. NSAID-related ulcers: Stop NSAID; start PPI or misoprostol if NSAIDs must continue. C. Complications / Procedures Bleeding: Endoscopic coagulation or clipping; IV PPI infusion afterward. Perforation: Surgical repair. Refractory or recurrent ulcers: Confirm eradication, exclude malignancy or gastrinoma.   Question A 45-year-old man presents with several weeks of epigastric pain that improves after meals but returns a few hours later. He takes ibuprofen daily for chronic back pain. He denies vomiting, hematemesis, or melena. Physical examination shows mild epigastric tenderness without peritoneal signs. Which of the following is the most appropriate next diagnostic test to confirm the underlying cause of this patient’s condition?

MAFLD / MASH (Metabolic Dysfunction–Associated Fatty Liver Disease / Steatohepatitis) 1. Background MAFLD: Hepatic steatosis in patients with metabolic dysfunction (obesity, diabetes, dyslipidemia, or insulin resistance). MASH: Inflammatory subtype with hepatocellular injury and fibrosis. Replaces NAFLD/NASH terminology; alcohol intake no longer used to exclude diagnosis. Pathophysiology: Insulin resistance → increased fatty acid influx → triglyceride accumulation → oxidative stress → inflammation and fibrosis. Epidemiology: Most common liver disease in the U.S.; associated with metabolic syndrome, obesity, and diabetes. 2. History Often asymptomatic or presents with fatigue or mild RUQ discomfort. Risk factors: Central obesity, type 2 diabetes, dyslipidemia, hypertension, PCOS. Medications that worsen steatosis: corticosteroids, methotrexate, tamoxifen, amiodarone. 3. Exam Findings Mild hepatomegaly early. Advanced disease: jaundice, ascites, spider angiomas, palmar erythema, gynecomastia, splenomegaly. 4. Diagnosis Labs Mild elevation of AST/ALT (usually AST Late (fibrosis): AST > ALT Normal bilirubin and ALP unless advanced. Screen for metabolic syndrome (A1c, fasting glucose, lipids). Imaging Ultrasound: Increased echogenicity (“bright liver”). FibroScan (elastography): Measures fibrosis noninvasively. CT/MRI: Detects fat but not inflammation. Biopsy (if needed): Steatosis with ballooning degeneration, Mallory-Denk bodies, lobular inflammation, and pericellular fibrosis (MASH pattern). Diagnostic Criteria (2023): Evidence of hepatic steatosis plus one of: Overweight/obesity Type 2 diabetes ≥2 features of metabolic dysregulation (↑ waist circumference, dyslipidemia, insulin resistance, ↑ CRP, etc.) 5. Management Lifestyle (First-line) Weight loss ≥10% → improves steatohepatitis and fibrosis. Diet: Mediterranean or low-carbohydrate. Exercise: ≥150 minutes/week moderate activity. Avoid alcohol and hepatotoxic drugs. Pharmacologic Pioglitazone: For biopsy-proven MASH with T2DM. GLP-1 agonists (semaglutide): Reduce steatosis and promote weight loss. Vitamin E (800 IU/day): For non-diabetic MASH. No FDA-approved drug yet (as of 2025). Comorbidity Management Optimize glucose, lipids, and blood pressure (statins are safe). Monitoring / Surveillance Elastography every 1–2 years to assess fibrosis. HCC surveillance (ultrasound ± AFP every 6 months) if cirrhosis develops. Liver transplant for end-stage disease. Question A 49-year-old woman with obesity, hypertension, and type 2 diabetes presents for evaluation of mild fatigue. She denies alcohol use. Laboratory studies show: Test Result Reference Range ALT 68 U/L (7–56 U/L) AST 56 U/L (10–40 U/L) Alkaline phosphatase 98 U/L (44–147 U/L) Total bilirubin 0.8 mg/dL (0.2–1.2 mg/dL) Fasting glucose 152 mg/dL (70–99 mg/dL) Hemoglobin A1c 7.4% (

Choledocholithiasis 1. Background Definition: Presence of one or more gallstones in the common bile duct (CBD), leading to biliary obstruction. Pathophysiology: Secondary stones (most common): Migrated from the gallbladder via the cystic duct. Primary stones: Form within the CBD due to stasis or infection. Obstruction → bile stasis → ductal dilation and ↑ pressure → potential cholangitis or pancreatitis. Epidemiology: Occurs in ~10–15% of patients with gallstones. More common in middle-aged women and in patients with a history of cholelithiasis or cholecystectomy. 2. History Symptoms: RUQ or epigastric pain (colicky or steady), often following a fatty meal. Jaundice (fluctuating or progressive). Dark urine and pale stools due to conjugated hyperbilirubinemia. Nausea and vomiting. May be asymptomatic and discovered incidentally (e.g., elevated liver enzymes). Complications: Cholangitis: Fever, jaundice, RUQ pain (Charcot triad). Gallstone pancreatitis: Epigastric pain radiating to back with elevated lipase. 3. Exam Findings RUQ tenderness or mild epigastric tenderness. Jaundice and scleral icterus (key differentiator from uncomplicated cholecystitis). Murphy sign usually negative unless concurrent cholecystitis. Fever or hypotension if cholangitis develops (Charcot triad or Reynolds pentad). 4. Making the Diagnosis A. Laboratory Findings Cholestatic pattern: ↑ ALP and GGT (disproportionate to AST/ALT). ↑ Direct (conjugated) bilirubin. Mild elevation of AST/ALT possible. If pancreatitis: Elevated amylase/lipase. B. Imaging Test Role Ultrasound (first-line) Detects gallstones and dilated CBD (>6 mm); may not visualize CBD stones directly. MRCP (magnetic resonance cholangiopancreatography) Noninvasive, highly sensitive for CBD stones. Endoscopic ultrasound (EUS) Alternative for stone detection if MRCP unavailable or indeterminate. ERCP (endoscopic retrograde cholangiopancreatography) Gold standard for diagnosis and treatment (stone extraction). Used when diagnosis is likely or confirmed. C. Distinguishing Features Condition Key Findings Cholelithiasis Stones confined to gallbladder, no jaundice or LFT elevation Cholecystitis RUQ pain + fever, normal or mildly elevated LFTs, no duct dilation Choledocholithiasis Jaundice, ↑ ALP & bilirubin, dilated CBD Cholangitis Choledocholithiasis + infection (fever, leukocytosis, Charcot triad) 5. Management A. Initial Care NPO, IV fluids, analgesia, and broad-spectrum antibiotics if infection suspected. Correct coagulopathy and fluid/electrolyte imbalances. B. Definitive Therapy ERCP with sphincterotomy and stone extraction (diagnostic and therapeutic). Laparoscopic cholecystectomy after duct clearance to prevent recurrence (unless already removed). C. Alternatives Percutaneous transhepatic cholangiography (PTC): For patients not candidates for ERCP. Intraoperative cholangiography: Detects stones during cholecystectomy. D. Complications Acute cholangitis Gallstone pancreatitis Biliary cirrhosis (from chronic obstruction) E. Prevention Removal of gallbladder if source of recurrent stones. Adequate hydration and healthy diet to reduce stone formation risk. Question A 52-year-old woman presents with right upper quadrant abdominal pain, jaundice, and nausea for the past two days. She had a laparoscopic cholecystectomy 3 years ago. Her temperature is 99.9°F (37.7°C), blood pressure 118/72 mm Hg, and pulse 88/min. Physical exam reveals scleral icterus and mild right upper quadrant tenderness without guarding. Laboratory studies: AST: 96 U/L ALT: 112 U/L ALP: 480 U/L Total bilirubin: 5.2 mg/dL (direct 4.7 mg/dL) Ultrasound shows a dilated common bile duct (9 mm) without gallbladder. Which of the following is the most appropriate next step in management?